Alliance Pharma (LON:APH) Price Target Cut to GBX 105

Alliance Pharma (LON:APHGet Rating) had its price objective dropped by Berenberg Bank from GBX 110 ($1.34) to GBX 105 ($1.28) in a research report issued on Tuesday, MarketBeat.com reports. The firm currently has a “buy” rating on the stock. Berenberg Bank’s target price points to a potential upside of 73.55% from the stock’s previous close.

Alliance Pharma Stock Performance

LON:APH opened at GBX 60.50 ($0.74) on Tuesday. The stock has a fifty day moving average price of GBX 52.79 and a 200-day moving average price of GBX 71.88. The company has a market cap of £326.70 million and a price-to-earnings ratio of 3,025.00. The company has a debt-to-equity ratio of 45.88, a quick ratio of 1.42 and a current ratio of 1.93. Alliance Pharma has a fifty-two week low of GBX 34.14 ($0.42) and a fifty-two week high of GBX 122 ($1.49).

About Alliance Pharma

(Get Rating)

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products.

Featured Stories

Receive News & Ratings for Alliance Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliance Pharma and related companies with MarketBeat.com's FREE daily email newsletter.